- 期刊
- OpenAccess
New Long-acting Basal Insulin Analogues: A Review of Their Roles in Clinical Application
摘要
Background. A proportion of patients with diabetes mellitus might need basal insulin to achieve glycemic control. Traditional intermediate-acting human insulins such as neutral protamine Hagedorn insalin demonstrate unfavorable pharmacokinetics. Long-acting insulin analogues provide therapeutic advantage over human insulins. Recently, new-generation long-acting insulin analogues are emerging in the market. We review the clinical profiles of three novel insulin analogues (insulin glargine 300 units/mL, insulin degludec, and basal insulin peglispro) for diabetes management. Findings. When compared with glargine 100 units/mL, insulin glargine 300 units/mL has similar potency in glycemic control but has lower risk of hypoglycemia and less weight gain. Insulin degludec also improves glycemic control correspondingly to insulin glargine 100 units/mL. Basal insulin peglispro seems to reduce HbA1c better than insulin glargine 100 units/mL with a low risk of hypoglycemia. However, basal insulin peglispro is associated with increased risk of hypertriglyceridemia and hepatitis. Its development was terminated in 2015 due to these side effects. Conclusion. Both insulin glargine 300 units/mL and insulin degludec are effective for glycemic control with lower risk of hypoglycemia when compared with insulin glargine 100 units/mL. Insulin glargine 300 units/mL, but not Insulin degludec, may associate with less weight gain.